Edgewise Therapeutics Inc (EWTX)
17.13
-0.37
(-2.11%)
USD |
NASDAQ |
May 31, 16:00
17.14
+0.01
(+0.06%)
After-Hours: 20:00
Edgewise Therapeutics Cash from Investing (Quarterly): -268.31M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -268.31M |
| December 31, 2023 | 26.98M |
| September 30, 2023 | 23.42M |
| June 30, 2023 | 3.442M |
| March 31, 2023 | 49.04M |
| December 31, 2022 | -75.60M |
| September 30, 2022 | -26.32M |
| June 30, 2022 | -0.046M |
| March 31, 2022 | 31.39M |
| Date | Value |
|---|---|
| December 31, 2021 | 14.12M |
| September 30, 2021 | -31.61M |
| June 30, 2021 | -159.97M |
| March 31, 2021 | -64.77M |
| December 31, 2020 | -24.18M |
| September 30, 2020 | -0.006M |
| June 30, 2020 | -0.188M |
| March 31, 2020 | -0.009M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-268.31M
Minimum
Mar 2024
49.04M
Maximum
Mar 2023
-29.57M
Average
-0.046M
Median
Jun 2022
Cash from Investing (Quarterly) Benchmarks
| Pfizer Inc | 1.732B |
| Sarepta Therapeutics Inc | 218.80M |
| PTC Therapeutics Inc | -114.93M |
| Regenxbio Inc | 13.18M |
| Alnylam Pharmaceuticals Inc | -67.62M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -28.60M |
| Cash from Financing (Quarterly) | 241.07M |
| Free Cash Flow | -99.39M |
| Free Cash Flow Per Share (Quarterly) | -0.33 |
| Free Cash Flow Yield | -8.31% |